By Salim S. Abdool Karim, M.B., Ch.B., Ph.D., and Nikita Devnarain, Ph.D. In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the...
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
By Carolyn T. Bramante, M.D., M.P.H., et al. Abstract BACKGROUND Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic....
FDA allows pharmacists to prescribe Paxlovid COVID treatment
By Oriana Gonzalez The Food and Drug Administration said Wednesday it's allowing state-authorized pharmacists to prescribe Pfizer's antiviral treatment Paxlovid. Driving the news: It's a win for pharmacies, which had been pushing for the FDA to allow...
What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment
The recurring symptoms are usually milder than the initial illness—but you may still be contagious. By Julia Ries Some patients who have taken Pfizer's Paxlovid medication—an antiviral drug used to prevent severe illness from COVID-19—have experienced a recurrence in...
Rebound COVID Is Just the Start of Paxlovid’s Mysteries
There’s plenty more to learn about the lifesaving antiviral COVID treatment. By Rachel Gutman The first data on Paxlovid, out last November, hinted that the COVID antiviral would cut the risk of hospitalization and death by 89 percent. Pundits called the drug...
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return
By Zoey Becker The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company's antiviral Paxlovid. After reports said some patients who took Paxlovid rebounded and...
FAMOTIDINE SHOWN TO SIGNIFICANTLY DECREASE COVID SYMPTOMS IN 55-PATIENT RANDOMIZED TRIAL
Famotidine, the over-the-counter heartburn drug, pepcid, was shown to significantly decrease COVID symptoms in a 55-patient randomized trial authored by Dr. Tobias Janowitz and published in the BMJ journal Gut February 10, 2022. Famotidine has been...
Honduras Reduced COVID Deaths With Repurposed Drugs, Early Treatment
Dr. Fernando Valerio, a critical care doctor in Honduras who co-authored a recent peer-reviewed study indicating the potential of repurposed drugs targeting SARS-CoV-2, shared with Trial Site his experience treating patients in the Central American nation....
Concern as Republicans push to make dubious Covid cure prescriptions easier
Ivermectin and hydroxychloroquine, the cures in question, have proven to be ineffective in preventing or treating Covid-19 By Eric Berger Republican state lawmakers across the United States have proposed – and in some cases passed – legislation that they say keeps the...
NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment
Recently, an international trial site network known as the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) completed a global study revealing that remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2...
TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants
TFF Pharmaceuticals announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases. TFF develops...
Paxlovid Cleared for Conditional Use in Europe
Paxlovid, the oral Pfizer treatment for COVID-19, appears headed for emergency use authorization in Europe. Conditional Marketing Authorization for Paxlovid The European Medical Agency’s (EMA) human medicines committee (CHMP) recommended Pfizer Europe MA EEIG...
University of Calgary Repurposed Drug Breakthrough: Hydroxychloroquine Delays Severe Forms of Multiple Sclerosis
What if a relatively low-cost, repurposed drug could help treat multiple sclerosis (MS), the least treatable of all autoimmune diseases? That could be a distinct possibility now that Dr. Marcus Koch, MD, Ph.D., and Dr. Wee Yong, Ph.D., with Cummings School of Medicine...
Merck Inks Deal with Bangladeshi Pharma to Distribute Molnupiravir to 100+ Countries Targeting Important COVID-19 Antiviral Market
With a great demand for antivirals targeting early-onset COVID-19, Merck inked a sub-licensing deal with one of the largest pharmaceutical companies in Bangladesh to produce Molnupiravir (Lagevrio) for distribution to over 100 nations. The deal, part of the Medicine...
Merck’s COVID-19 pill to be produced by more than two dozen drugmakers
BY MONIQUE BEALS Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing...